$59.92
0.03% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Stock price

$59.92
+11.37 23.42% 1M
+23.16 63.00% 6M
+13.95 30.35% YTD
+25.88 76.03% 1Y
+49.78 490.93% 3Y
+36.57 156.56% 5Y
+29.92 99.73% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.02 0.03%
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Key metrics

Market capitalization $3.68b
Enterprise Value $3.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 32.34
P/S ratio (TTM) P/S ratio 32.72
P/B ratio (TTM) P/B ratio 328.24
Revenue growth (TTM) Revenue growth 81.55%
Revenue (TTM) Revenue $112.53m
EBIT (operating result TTM) EBIT $-265.52m
Free Cash Flow (TTM) Free Cash Flow $-124.42m
Cash position $298.39m
EPS (TTM) EPS $-4.34
P/E forward negative
P/S forward 29.59
EV/Sales forward 29.24
Short interest 20.57%
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
113 113
82% 82%
100%
- Direct Costs 14 14
69% 69%
12%
99 99
83% 83%
88%
- Selling and Administrative Expenses 137 137
25% 25%
122%
- Research and Development Expense 226 226
77% 77%
201%
-264 -264
44% 44%
-235%
- Depreciation and Amortization 1.60 1.60
20% 20%
1%
EBIT (Operating Income) EBIT -266 -266
43% 43%
-236%
Net Profit -259 -259
40% 40%
-230%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Neutral
Investors Business Daily
8 days ago
This biotech stock is back in a buy zone after a sharp sell-off. The company makes an obesity drug and develops treatments for rare diseases.
Neutral
GlobeNewsWire
8 days ago
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to evaluate setmelanotide therapy in patients with congenital hypothalamic obesity --
Neutral
GlobeNewsWire
13 days ago
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages...
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 226
Founded 2008
Website www.rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today